Zevra Therapeutics (NASDAQ:ZVRA) CEO Sells 91,000 Shares

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) CEO Neil Mcfarlane sold 91,000 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $9.38, for a total transaction of $853,580.00. Following the completion of the transaction, the chief executive officer owned 364,350 shares of the company’s stock, valued at approximately $3,417,603. The trade was a 19.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Zevra Therapeutics Price Performance

Shares of Zevra Therapeutics stock traded up $0.36 during trading hours on Monday, hitting $9.36. The company’s stock had a trading volume of 1,074,144 shares, compared to its average volume of 1,039,668. The company has a market cap of $526.97 million, a PE ratio of 19.91 and a beta of 0.99. The company has a debt-to-equity ratio of 0.46, a quick ratio of 8.57 and a current ratio of 8.62. The business has a 50 day moving average price of $8.64 and a two-hundred day moving average price of $9.45. Zevra Therapeutics, Inc. has a 12-month low of $6.19 and a 12-month high of $13.16.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. The company had revenue of $26.06 million for the quarter, compared to analysts’ expectations of $26.64 million. Zevra Therapeutics had a negative return on equity of 51.40% and a net margin of 41.93%. Analysts expect that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zevra Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. UBS Group AG boosted its holdings in Zevra Therapeutics by 30.9% during the 4th quarter. UBS Group AG now owns 285,488 shares of the company’s stock valued at $2,558,000 after acquiring an additional 67,392 shares during the period. Sanctuary Advisors LLC lifted its position in shares of Zevra Therapeutics by 18.0% during the fourth quarter. Sanctuary Advisors LLC now owns 34,461 shares of the company’s stock worth $309,000 after purchasing an additional 5,247 shares during the last quarter. Retirement Planning Co of New England Inc. boosted its stake in shares of Zevra Therapeutics by 10.4% during the fourth quarter. Retirement Planning Co of New England Inc. now owns 662,976 shares of the company’s stock valued at $5,940,000 after purchasing an additional 62,206 shares during the period. Stratos Wealth Partners LTD. grew its holdings in shares of Zevra Therapeutics by 78.6% in the fourth quarter. Stratos Wealth Partners LTD. now owns 409,000 shares of the company’s stock worth $3,665,000 after purchasing an additional 180,000 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. purchased a new position in Zevra Therapeutics in the 4th quarter worth about $1,251,000. 35.03% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ZVRA has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Zevra Therapeutics in a report on Friday, January 9th. Cantor Fitzgerald cut their target price on shares of Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. Canaccord Genuity Group decreased their price target on shares of Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research note on Thursday, November 6th. HC Wainwright set a $26.00 price objective on shares of Zevra Therapeutics in a research note on Tuesday, December 30th. Finally, Wall Street Zen upgraded shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.80.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.